Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.The pharmaceutical company, however,

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across its Growth Portfolio, prompting the pharmaceutical giant to raise its full-year guidance.